Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

lassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL per min.

Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. If this drug is used during pregnancy or if a patient becomes pregnant, the patient should be apprised of the potential hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

Most common adverse reactions (more than 40%) in adult patients receiving either PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia, and anxiety/emotional lability/irritability. Most common adverse reactions (more than 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting.

In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; however, the majority of these cases were mild and responded to dose reductions. The incidence of serious adverse reactions reported for the weight-based REBETOL group was 12%. In many but not all cases, adverse reactions resolved after dose reduction or
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... KING OF PRUSSIA, Pa., March 21, 2011 ... higher dose Hizentra® (IgPro 20) correlates with reduced risk of ... immunodeficiencies (PI). These data, presented at the 2011 ... from two recent trials of Hizentra , one performed ...
... Inc. (NYSE: WPI ) today confirmed that ... 125 mg, 250 mg and 500 mg, the generic ... New Drug Application (ANDA) by the U.S. Food and ... today. Famciclovir is an antiviral used in the treatment ...
Cached Medicine Technology:Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 2Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 3Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 4Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 5Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 6Watson Launches Generic Famvir® 2
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... holiday party season fast approaching, a new study reveals that ... arrests have fewer drunk drivers on their roads. The ... vigilantly are better able to deter inebriated revelers from getting ... new laws are being passed regarding drinking and driving," said ...
(Date:12/15/2014)... A recent survey found that the ... impacting skin health and beauty were: “Connections,” “climate,” “career” ... Water and health advocate and radio host Sharon Kleyne ... the survey and the Four C’s.* Kleyne notes, however, ... discussed would benefit from paying attention to one’s daily ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first ... study providing evidence on the impact of 100% pure ... Sufficient enough evidence already exists showing a negative link ... with the onset of tooth decay. One question that ... 100% fruit juice, meaning it is completely natural with ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... & Public Policy Center and the Coalition for ... "get personalized medicine right," Health and Human Services ... implement a reasonable and responsible regulatory framework" for ... diverse coalition of more than a hundred organizations ...
... HARBOR, N.Y. (May 5, 2009) The ... provide a supportive yet flexible framework that allows vertebrates ... knowledge about the vertebrate skeleton, especially recent research on ... a new monograph, The Skeletal System . ...
... CITY, Mo., May 5 Argus Health Systems, Inc., ... announced that Laura Topor has been elected to the ... Trustees for a three-year term. The Board of Trustees ... Council industry standardization development activities. Prior to the election, ...
... May 5 The National Federation of the Blind (NFB) ... Motown group Martha and the Vandellas, will take the stage ... The third annual Motor City ... of July 6, 2009, as part of the National Federation ...
... Bates County Memorial Hospital (BCMH), a ... the MedGenix financial and patient management system. The MedGenix ... cycle management and financial accounting modules. The MedGenix ... Systems (CHS), based in Springfield, MO. Founded in 1992, ...
... Inc. (OTC Bulletin Board: AEMD) today disclosed new ... the Aethlon Hemopurifier(R) to treat Human Immunodeficiency Virus ... Syndrome (AIDS). Aethlon announced that an HIV-infected ... span of one month, had an average viral ...
Cached Medicine News:Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 2Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 3Health News:New book summarizes current knowledge on the biology of the vertebrate skeleton 2Health News:Martha Reeves to Participate in the National Federation of the Blind Motor City March for Independence 2Health News:MedGenix Financial Information System Selected by Bates County Memorial Hospital 2Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 2Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 3Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 4Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 5
... watt xenon Light Source. ... your commitment to provide every ... care available through our ongoing ... surgical instruments and diagnostic solutions., ...
The new X7000 light source is specifically tuned for the demanding requirements of Progressive Scan High Definition. The X7000 Lightsource uses a 300 Watt Xenon Elliptical Bulb for crystal clear illu...
... 175 watt xenon Light ... , ,SOLOS Endoscopy shares ... patient with the highest quality ... research and development of advanced ...
... need to standardize your video equipment has ... of optical couplers to accommodate all of ... "C and "V mount couplers in both ... designs. We also offer a 20-42mm Zoom ...
Medicine Products: